

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

CAMBRIDGE, Mass., April 1, 2025 /PRNewswire/ -- [Nuvalent, Inc.](#) (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating *precisely* targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Stifel 2025 Virtual Targeted Oncology Forum on Tuesday, April 8, 2025, at 2:30 p.m. ET.

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentations.

About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating *precisely* targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

SOURCE Nuvalent, Inc.

Investor Contact:

Chelcie Lister
Nuvalent, Inc.
clister@nuvalent.com

Media Contact:

Josie Butler
1AB
josie@1abmedia.com

<https://investors.nuvalent.com/2025-04-01-Nuvalent-to-Participate-in-the-Stifel-2025-Virtual-Targeted-Oncology-Forum>